Laura Shapiro Kulnane
Case Western Reserve University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laura Shapiro Kulnane.
Neuron | 2006
Ahmad Salehi; Jean Dominique Delcroix; Pavel V. Belichenko; Ke Zhan; Chengbiao Wu; Janice S. Valletta; Ryoko Takimoto-Kimura; Alexander M. Kleschevnikov; Kumar Sambamurti; Peter Chung; Weiming Xia; Angela J. Villar; William A. Campbell; Laura Shapiro Kulnane; Ralph A. Nixon; Bruce T. Lamb; Charles J. Epstein; Gorazd B. Stokin; Lawrence S.B. Goldstein; William C. Mobley
Degeneration of basal forebrain cholinergic neurons (BFCNs) contributes to cognitive dysfunction in Alzheimers disease (AD) and Downs syndrome (DS). We used Ts65Dn and Ts1Cje mouse models of DS to show that the increased dose of the amyloid precursor protein gene, App, acts to markedly decrease NGF retrograde transport and cause degeneration of BFCNs. NGF transport was also decreased in mice expressing wild-type human APP or a familial AD-linked mutant APP; while significant, the decreases were less marked and there was no evident degeneration of BFCNs. Because of evidence suggesting that the NGF transport defect was intra-axonal, we explored within cholinergic axons the status of early endosomes (EEs). NGF-containing EEs were enlarged in Ts65Dn mice and their App content was increased. Our study thus provides evidence for a pathogenic mechanism for DS in which increased expression of App, in the context of trisomy, causes abnormal transport of NGF and cholinergic neurodegeneration.
Nature Neuroscience | 1999
Bruce A. Lamb; Kimberly A. Bardel; Laura Shapiro Kulnane; Jeffrey Anderson; Greg Holtz; Steven L. Wagner; Sangram S. Sisodia; Emily J. Hoeger
Dosage imbalance for chromosome 21 in Down syndrome and mutations in the amyloid precursor protein (APP) and presenilin-1 (PS-1) genes in early-onset familial Alzheimers disease (FAD) result in elevated production and deposition of amyloid-β (Aβ) peptides, particularly the 42 amino acid form, Aβ1–42. One difficulty in studying the generation and deposition of Aβ, neuritic abnormalities, synaptic dysfunction, neuronal cell death and dementia that occurs in Alzheimers disease (AD) is the paucity of small animal models. To examine effects of the FAD mutations in vivo, we transferred yeast artificial chromosomes (YACs) containing the entire genomic copy of human APP and/or PS-1 genes harboring FAD mutations into transgenic mice. We now document that a mutant APP YAC transgenic mouse develops Aβ deposits and that this deposition is accelerated when the animals are mated to homozygosity and/or to mutant PS-1 YAC transgenic mice.
Neurobiology of Disease | 2001
Laura Shapiro Kulnane; Bruce T. Lamb
Mutations in the amyloid precursor protein (APP) gene result in elevated production and deposition of the 42 amino acid beta-amyloid (Abeta1-42) peptide and early-onset Alzheimers disease (AD). To accurately examine the effect of the APP FAD mutations in vivo, we introduced yeast artificial chromosomes (YACs) containing the entire genomic copy of human APP harboring FAD mutations into transgenic mice. Our current results demonstrate that mutant APP YAC transgenic mice exhibit many features characteristic of human AD, including regional deposition of Abeta with preferential deposition of Abeta1-42, extensive neuritic abnormalities as evidenced by staining with APP, ubiquitin, neurofilament, and hyperphosphorylated tau antibodies, increased markers of inflammation, and the overlapping deposition of Abeta with apolipoproteins E and J. Our results also suggest that APP YAC transgenic mice possess unique pathological attributes when compared to other transgenic mouse models of AD that may reflect the experimental design of each model.
Neurobiology of Aging | 2003
Emily J H Lehman; Laura Shapiro Kulnane; Bruce T. Lamb
Mutations in the amyloid precursor protein (APP) gene are associated with altered production and deposition of amyloid beta (Abeta) peptide in the Alzheimers disease (AD) brain. The pathways that regulate APP processing, Abeta production and Abeta deposition in different tissues and brain regions remain unclear. To address this, we examined levels of various APP processing products as well as Abeta deposition in a genomic-based (R1.40) and a cDNA-based (Tg2576) transgenic mouse model of AD. In tissues, only brain generated detectable levels of the penultimate precursor to Abeta, APP C-terminal fragment-beta. In brain regions, holoAPP levels remained constant, but ratios of APP C-terminal fragments and levels of Abeta differed significantly. Surprisingly, cortex had the lowest steady-state levels of Abeta compared to other brain regions. Comparison of Abeta deposition in Tg2576 and R1.40 animals revealed that R1.40 exhibited more abundant deposition in cortex while Tg2576 exhibited extensive deposition in the hippocampus. Our results suggest that AD transgenic models are not equal; their unique characteristics must be considered when studying AD pathogenesis and therapies.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Johnnie Chau; Laura Shapiro Kulnane; Helen K. Salz
Drosophila ovarian germ cells require Sex-lethal (Sxl) to exit from the stem cell state and to enter the differentiation pathway. Sxl encodes a female-specific RNA binding protein and in somatic cells serves as the developmental switch gene for somatic sex determination and X-chromosome dosage compensation. None of the known Sxl target genes are required for germline differentiation, leaving open the question of how Sxl promotes the transition from stem cell to committed daughter cell. We address the mechanism by which Sxl regulates this transition through the identification of nanos as one of its target genes. Previous studies have shown that Nanos protein is necessary for GSC self-renewal and is rapidly down-regulated in the daughter cells fated to differentiate in the adult ovary. We find that this dynamic expression pattern is limited to female germ cells and is under Sxl control. In the absence of Sxl, or in male germ cells, Nanos protein is continuously expressed. Furthermore, this female-specific expression pattern is dependent on the presence of canonical Sxl binding sites located in the nanos 3′ untranslated region. These results, combined with the observation that nanos RNA associates with the Sxl protein in ovarian extracts and loss and gain of function studies, suggest that Sxl enables the switch from germline stem cell to committed daughter cell by posttranscriptional down-regulation of nanos expression. These findings connect sexual identity to the stem cell self-renewal/differentiation decision and highlight the importance of posttranscriptional gene regulatory networks in controlling stem cell behavior.
Genetics | 2009
Johnnie Chau; Laura Shapiro Kulnane; Helen K. Salz
In Drosophila, the female-specific SEX-LETHAL (SXL) protein is required for oogenesis, but how Sxl interfaces with the genetic circuitry controlling oogenesis remains unknown. Here we use an allele of sans fille (snf) that specifically eliminates SXL protein in germ cells to carry out a detailed genetic and cell biological analysis of the resulting ovarian tumor phenotype. We find that tumor growth requires both Cyclin B and zero population growth, demonstrating that these mutant cells retain at least some of the essential growth-control mechanisms used by wild-type germ cells. Using a series of molecular markers, we establish that while the tumor often contains at least one apparently bona fide germline stem cell, the majority of cells exhibit an intermediate fate between a stem cell and its daughter cell fated to differentiate. In addition, snf tumors misexpress a select group of testis-enriched markers, which, remarkably, are also misexpressed in ovarian tumors that arise from the loss of bag of marbles (bam). Results of genetic epistasis experiments further reveal that bams differentiation-promoting function depends on Sxl. Together these data demonstrate a novel role for Sxl in the lineage progression from stem cell to committed daughter cell and suggest a model in which Sxl partners with bam to facilitate this transition.
Current Aging Science | 2009
Brian J. Hock; K. Matthew Lattal; Laura Shapiro Kulnane; Ted Abel; Bruce T. Lamb
To gain insight into the relationship between pathological alterations and memory deficits observed in Alzheimers disease (AD), a number of amyloid precursor protein (APP) transgenic animal models have been generated containing familial AD mutations. The most commonly utilized method involves a cDNA-based approach, utilizing heterologous promoters to drive expression of specific APP isoforms. As a result of the assumptions inherent in the design of each model, the different cDNA-based transgenic mouse models have revealed different relationships between the biochemical, pathological and behavioral alterations observed in these models. Here we provide further characterization of a genomic-based, amyloid precursor protein yeast artificial chromosome transgenic mouse model of AD, R1.40, that makes few assumptions regarding disease pathogenesis to study the relationship between brain pathology and altered behavior. Aged R1.40 transgenic and control mice were tested for learning and memory in the Morris water maze and for working memory in the Y maze. Results from the water maze demonstrated intact learning in the both control and R1.40 mice, but impairments in the long-term retention of this information in the transgenic mice, but not controls. Interestingly, however, long-term memory deficits did not correlate with the presence of Abeta deposits within the group of animals examined. By contrast, age-related working memory impairments were also observed in the Y maze in the R1.40 mice, and these deficits correlated with the presence of Abeta deposits. Our results demonstrate unique behavioral alterations in the R1.40 mouse model of AD that are likely both dependent and independent of Abeta deposition.
Human Molecular Genetics | 2003
Emily J H Lehman; Laura Shapiro Kulnane; Yuan Gao; Michelle C. Petriello; Karen M. Pimpis; Linda Younkin; Georgia Dolios; Rong Wang; Steven G. Younkin; Bruce T. Lamb
Journal of Biological Chemistry | 2004
Matthew J. Chiocco; Laura Shapiro Kulnane; Linda Younkin; Steve Younkin; Genevieve Evin; Bruce T. Lamb
Mammalian Genome | 2002
Laura Shapiro Kulnane; Emily J H Lehman; Brian J. Hock; Karen Tsuchiya; Bruce T. Lamb